TIMP3 and prostate cancer: Although the TIMP3 rs9619311 polymorphism was not significantly associated with the clinicopathological characteristics of the 579 prostate cancer patients in this study (Table 4), it was associated with total score upgrade (p = 0.012; OR: 3.007; 95% CI: 1.243–7.274) and grade group upgrade (p = 0.023; OR: 2.724; 95% CI: 1.128–6.581) in cohort with PSA concentrations under 7 ng/mL (Table 6).